- Sharing the role of technology and partnerships in the design & recruitment of studies.
- Highlighting adaptive trial designs, decentralized models, and inclusive recruitment strategies.
- Exploring how smarter trial design accelerates approval, reduces risk, and improves real-world outcomes.
- Discover how real-world data, genomics, and AI are revealing new targets and mechanisms in female-specific and reproductive conditions.
- Learn how data integration is shortening timelines from target identification to preclinical validation.
- Sharing insights into novel drug discovery approaches, the use of AI, multi-omics data, and 3D models.
Reproductive Health
Drug Development
Stasa Stankovic
Chief Executive Officer
Ovartix
Mark Eccleston
Chief Executive Officer
ValiRx
- Explore the mechanism of action and preclinical efficacy of a first-in-class oncolytic peptide targeting triple negative breast cancer (TNBC).
- Understand how peptide-based approaches offer new hope for aggressive and treatment-refractory subtypes of breast cancer.
- Learn about the breast cancer therapeutic roadmap and landscape.
Oncology
Drug Development
Mark Eccleston
Chief Executive Officer
ValiRx
Oliver Bates
Chief Executive Officer
Viramal
- Learn how to align clinical development strategies with licensing milestones to accelerate commercialization in women’s health.
- Explore what pharma and late stage investors look for in licensing-ready assets, from early efficacy signals to regulatory preparedness.
- Understand how to navigate clinical, legal, and market access challenges unique to women’s health to build a compelling licensing case.
Drug Development
Oliver Bates
Chief Executive Officer
Viramal
Carrie Nixon
Founder & CEO
Nixon Law Group
Luke Quinn
Head of Business Solutions
Agreena
Agreena
Website: http://www.agreena.com
Headquartered in Denmark, Agreena is powering the global transition to regenerative agriculture, operating Europe’s leading soil carbon programme. Through its flagship AgreenaCarbon project, which is the first large-scale agricultural cropland initiative registered under Verra's world-renowned Verified Carbon Standard, Agreena collaborates with thousands of farmers across 4.5 million hectares of arable land in 20 markets.
Agreena finances farmers’ transition to sustainable practices, measures and verifies the climate impact with field-level accuracy, and offers climate solutions to corporates to achieve their sustainability goals.
Agreena’s holistic solution is built on three pillars: farmer engagement, which provides essential financing, knowledge, and resources to support growers in making impactful change; scalable dMRV, integrating satellite imagery, ground-level soil sampling and proprietary AI models to precisely quantify practice changes and carbon outcomes at scale; and verified carbon and environmental data, empowering companies to make credible sustainability claims, support farmer-led climate action and access high-integrity carbon credits.